Lakefront Biotherapeutics (LKFT) Asset Utilization Ratio (2016 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Asset Utilization Ratio of 0.31 for Q1 2026, up 460.23% year-on-year from 0.05 in Q1 2025, and down 4.23% on a QoQ basis from 0.32 in Q4 2025.
Lakefront Biotherapeutics (LKFT) Asset Utilization Ratio (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Asset Utilization Ratio for 10 consecutive years, with 0.31 the latest figure, recorded in Q1 2026.
- Quarterly Asset Utilization Ratio rose 460.23% year-over-year to 0.31 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.31 (up 460.23% YoY) and the FY2025 annual result came in at 0.29, up 354.37% from the prior year.
- Asset Utilization Ratio declined to 0.31 in Q1 2026 per LKFT's latest filing, from 0.32 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for LKFT reached as high as 0.32 in Q4 2025 and fell as low as 0.05 in Q4 2024.
- A 5-year average of 0.12 and a median of 0.07 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio dropped 23.17% — and 2025, when it jumped 531.04%.
- Year by year, Asset Utilization Ratio stood at 0.08 in 2022, then slipped by 12.16% to 0.07 in 2023, then dropped by 23.17% to 0.05 in 2024, then soared by 531.04% to 0.32 in 2025, then fell by 4.23% to 0.31 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.31, 0.32, and 0.06 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | 0.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.31 |
| Dec 31, 2025 | 0.32 |
| Sep 30, 2025 | 0.06 |
| Jun 30, 2025 | 0.09 |
| Mar 31, 2025 | 0.05 |
| Dec 31, 2024 | 0.05 |
| Mar 31, 2024 | 0.07 |
| Dec 31, 2023 | 0.07 |
| Mar 31, 2023 | 0.06 |
| Mar 31, 2022 | 0.08 |
| Dec 31, 2020 | 0.36 |
| Sep 30, 2020 | 0.21 |
| Jun 30, 2020 | 0.18 |
| Mar 31, 2020 | 0.17 |
| Dec 31, 2019 | 0.16 |
| Sep 30, 2019 | 0.27 |
| Jun 30, 2019 | 0.24 |
| Mar 31, 2019 | 0.24 |
| Dec 31, 2018 | 0.21 |
| Sep 30, 2018 | 0.19 |